TY - JOUR
T1 - Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome
T2 - evidence from the short-term results from the POLARIS Study
AU - Muso, Eri
AU - Mune, Masatoshi
AU - Hirano, Tsutomu
AU - Hattori, Motoshi
AU - Kimura, Kenjiro
AU - Watanabe, Tsuyoshi
AU - Yokoyama, Hitoshi
AU - Sato, Hiroshi
AU - Uchida, Shunya
AU - Wada, Takashi
AU - Shoji, Tetsuo
AU - Yuzawa, Yukio
AU - Takemura, Tsukasa
AU - Sugiyama, Satoshi
AU - Nishizawa, Yoshiki
AU - Ogahara, Satoru
AU - Yorioka, Noriaki
AU - Sakai, Soichi
AU - Ogura, Yosuke
AU - Yukawa, Susumu
AU - Iino, Yasuhiko
AU - Imai, Enyu
AU - Matsuo, Seiichi
AU - Saito, Takao
N1 - Funding Information:
This study was supported by The Kidney Foundation, Japan and in part by a grant in relation to Progressive Renal Disease from the Ministry of Health, Labor and Welfare Research Project for Specially Selected Disease. The authors express their appreciation to all the investigators who reported clinical data in this study, including Atsushi Oyama (Nishi-Kobe Medical Center), Noriaki Henmi (Fukaya Red Cross Hospital), Noriko Mori (Shizuoka General Hospital), Osamu Nishi, (Nishi Clinic), Yasukiyo Mori (Kyoto Prefectural University of Medicine), Megumu Fukunaga (Toyonaka Municipal Hospital), Masahiko Miyamoto (Osaka Red Cross Hospital), Kenji Arizono (Kumamoto Chuo Hospital), Takako Suzuki (Moriyama Rehabilitation Hospital), Kazuhiko Hora (Hokushin General Hospital), Hiroshi Makino (Okayama University), Hideyasu Kiyomoto (Kagawa University), Yutaka Ando (Osaka Minami Medical Center), Yoshiharu Tsubakihara (Osaka General Medical Center), Kosuke Ota (Okayama Medical Center), Masamichi Fukuda (Iwakuni Medical Center Hospital), Yukiko Abe (Shin-Oura Hospital), Mitsuhiro Yoneda (Fuke Chiba Hospital), Hiroshi Ohtani (Akita Kumiai General Hospital), Tokuichiro Sugimoto (Mitsui Memorial Hospital), Shizunori Ichida (Japanese Red Cross Nagoya Daiichi Hospital), Kentaro Wada (Nippon Kokan Fukuyama Hospital), Rhosuke Yoshihara (Konan Kakogawa Hospital), Shoichi Fujimoto (University of Miyazaki), Morihiro Kondo (Rakuwa-kai Otowa Hospital), Takeshi Nakanishi (Hyogo College of Medicine), Kazuhiko Tsuruya (Kyusyu University), Fumiki Tanigawa (Shimonoseki Kosei Hospital), Masami Hashimoto (Onomichi General Hospital), Akiko Nakamura (Saga Prefectural Hospital Koseikan), Soshi Yorifuji (Osaka Saiseikai Nakatsu Hospital), Tamaki Sasaki (Kawasaki Medical School).
Publisher Copyright:
© 2014, Japanese Society of Nephrology.
PY - 2015/6/17
Y1 - 2015/6/17
N2 - Background: Hyperlipidemia is not merely a complication but a major exacerbating factor in longstanding nephrotic syndrome (NS). Low-density lipoprotein apheresis (LDL-A) has been reported to ameliorate dyslipidemia and induce rapid remission of NS. Several clinical studies have suggested the therapeutic efficacy of LDL-A, but the level of clinical evidence is insufficient. Therefore, a multicenter prospective study, POLARIS (Prospective Observational Survey on the Long-Term Effects of LDL Apheresis on Drug-Resistant Nephrotic Syndrome), was initiated in Japan. Method: Patients with drug-resistant NS were prospectively recruited into the study and treated with LDL-A in facilities that were registered in advance. In the POLARIS study design, the clinical data are to be followed up for 2 years. In the current study, we aimed at evaluating the short-term efficacy based on the treatment outcome of LDL-A immediately after completion of treatment. Results: Along with rapid improvement of hyperlipidemia, LDL-A significantly improved proteinuria and hypoproteinemia after treatment. More than half of the patients showed remission of NS based on the urinary protein level at the completion of LDL-A. The duration of NS before the start of treatment was significantly shorter in patients who responded to LDL-A. Conclusions: An analysis of patients registered in the POLARIS study indicated that LDL-A has short-term efficacy for drug-resistant NS. Rapid relief of dyslipidemia by LDL-A may provide early remission in about half of the NS patients who are resistant to conventional medication. Completion of the POLARIS study may reveal additional long-term effects of LDL-A in these patients.
AB - Background: Hyperlipidemia is not merely a complication but a major exacerbating factor in longstanding nephrotic syndrome (NS). Low-density lipoprotein apheresis (LDL-A) has been reported to ameliorate dyslipidemia and induce rapid remission of NS. Several clinical studies have suggested the therapeutic efficacy of LDL-A, but the level of clinical evidence is insufficient. Therefore, a multicenter prospective study, POLARIS (Prospective Observational Survey on the Long-Term Effects of LDL Apheresis on Drug-Resistant Nephrotic Syndrome), was initiated in Japan. Method: Patients with drug-resistant NS were prospectively recruited into the study and treated with LDL-A in facilities that were registered in advance. In the POLARIS study design, the clinical data are to be followed up for 2 years. In the current study, we aimed at evaluating the short-term efficacy based on the treatment outcome of LDL-A immediately after completion of treatment. Results: Along with rapid improvement of hyperlipidemia, LDL-A significantly improved proteinuria and hypoproteinemia after treatment. More than half of the patients showed remission of NS based on the urinary protein level at the completion of LDL-A. The duration of NS before the start of treatment was significantly shorter in patients who responded to LDL-A. Conclusions: An analysis of patients registered in the POLARIS study indicated that LDL-A has short-term efficacy for drug-resistant NS. Rapid relief of dyslipidemia by LDL-A may provide early remission in about half of the NS patients who are resistant to conventional medication. Completion of the POLARIS study may reveal additional long-term effects of LDL-A in these patients.
UR - http://www.scopus.com/inward/record.url?scp=84931007441&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931007441&partnerID=8YFLogxK
U2 - 10.1007/s10157-014-0996-8
DO - 10.1007/s10157-014-0996-8
M3 - Article
C2 - 24934117
AN - SCOPUS:84931007441
VL - 19
SP - 379
EP - 386
JO - Clinical and Experimental Nephrology
JF - Clinical and Experimental Nephrology
SN - 1342-1751
IS - 3
ER -